hashimoto disease and glp 1 GLP-1 Agonists: The Medical Revolution Beyond Weight Loss GLP-1 medications can be powerful

Holst, MD', Healio

[1] Adverse effects [edit] Safety and dosing trials showed that the incidence of adverse events in orforglipron-treated participants was 6289%, mostly from gastrointestinal discomfort (4470% with orforglipron, 18% with placebo)

Cardiovascular Effects GLP-1-based therapies have been associated with slight increases in heart rate, which may be a concern for adolescents with underlying cardiovascular conditions

Refund policy

Efficacy and safety of Liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial